Last Updated : October 31, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Relapsed or refractory large B-cell lymphoma
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation
Therapeutic Area: Metastatic urothelial cancer
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation
Therapeutic Area: Metastatic colorectal cancer (mCRC)
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation
Therapeutic Area: Relapsed or refractory multiple myeloma
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation
Therapeutic Area: Chronic lymphocytic leukemia (CLL)
Draft recommendations posted for stakeholder feedback: October 31, 2024
End of feedback period: November 15, 2024
Draft Recommendation